Beating the Clock: Why Early-Phase CTA Strategy Now Decides the Companion Diagnostics Race

• Oncology drug approval timelines are accelerating making contemporaneous development of a companion diagnostic through traditional pathways more challenging
• Our focus will be accelerating early phase development and deployment of novel clinical trial assays, with early access to solutions that enable fast decision making and clinical trial startup
• Integrating digital pathology and AI solutions into IHC assay development to get more bang for your biomarker buck

Speakers:

T. Scott Reid

Vice President & Global Head of Companion Diagnostics

Discovery Life Sciences Inc